COVID-19: Evotec Share Price Jumps After Winning a Grant from Bill Gates Foundation

Shares of Evotec SE (ETR: EVT) gained around 2% on Monday after the company said it secured a grant from the Bill & Melinda Gates Foundation.

Evotec will use funds to support its US-based subsidiary Just to work on identifying and developing potential monoclonal antibody drugs for the prevention of severe COVID-19.

“Evotec Biologics will use its proprietary software toolset Abacus™ to perform an in silico analysis of several lead candidate sequences of potent anti-SARS-CoV-2 mAbs provided to the foundation by several leading academic medical centres around the world.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

“Abacus™ analysis will identify key sequences that can impact developability and, if required, make recommendations to optimise the anti-SARS-CoV-2 antibody candidates. In addition, Just – Evotec Biologics will perform cell line development for two lead molecules,” the company said in a statement.

Antibody drugs came into the spotlight after the U.S. President Donald Trump was treated with a cocktail of Regeneron’s antibody drugs.

Evotec share price gained over 2% to trade at €23.60 today.

PEOPLE WHO READ THIS ALSO VIEWED:

• Here’s Why Just Eat Takeaway Share Price Just Soared to Fresh Record Highs
• Experience stock trading with a reliable demo account
• Implement Divergence Trading strategy in your daily trading plan